However, it is important to highlight the need of further studies and clinical trials to define, for each subtype of HNSCC tumor, the actual diagnostic and predictive value of DAPK and MGMT as well as its viability and efficacy in clinical management. This evidence concerns the gene MGMT and head and neck squamous cell carcinoma.